Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)

NCT03316729 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT03316729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03316729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2018
Completion date
February 29, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism